'Old News'
Analysts say Times' accusatory articles on Zyprexa are nothing to get excited about.
Opening the Floodgates
FDA's revisions to guidelines on expanding access to experimental drugs intensify an already murky issue for pharma.
Staying the Course
At its annual pipeline debut, the company introduced its own CETP-inhibitor--with doubts.
